Korean Cosmetic Ingredient Restrictions for US Indie Founders (2026)

By the ALTA MEET editorial team | K-beauty ODM consulting

Every Korean ODM quote sheet references “Korean Cosmetic Act compliance” as a given. What most US indie founders miss is that the Korean Cosmetic Act is not a single ingredient list. It is a layered rulebook with a positive-list for functional ingredients, a very long prohibited list, a restricted list with concentration caps, a separate hair-dye annex, and a functional-cosmetic pre-review pathway that runs parallel to the FDA MOCRA regime you already have to file under. A Korean ODM will handle the Korean side by default. The US side is your problem, and the two lists do not overlap the way most founders assume.

This piece walks through what the Korean Cosmetic Act actually restricts as of 2026, where the current version of each list lives, and the specific documentation you should demand from your ODM to keep your MOCRA safety substantiation file intact when you sell into the United States.

What Does the Korean Cosmetic Act Actually Regulate in 2026?

The Korean Cosmetic Act (“화장품법”) is the statute administered by the Ministry of Food and Drug Safety (MFDS) that governs any cosmetic product manufactured, imported, or sold in South Korea. It is the primary reference every Korean ODM formulates against, and it controls three product-facing decisions that flow directly into your US SKU: which ingredients you can use, at what concentration, and whether your intended claim triggers Korea’s separate functional-cosmetic review.

MFDS Notification No. 2026-16, effective March 18, 2026, is the current binding version of the “Regulation on Safety Standards, etc. for Cosmetics.” The 2026 amendment reorganized the prohibited and restricted lists, clarified the hair-dye ingredient annex, added a new UV filter to the positive list, and updated official test methods for several substances. This is the document your Korean ODM is checking your formula against before it clears QC (source: ChemLinked regulatory summary).

The Act itself defines a “cosmetic” more narrowly than the US does. Products intended to treat, prevent, or diagnose disease fall into the “drug” category and land under a completely different statute. This distinction matters when you brief a Korean ODM on an anti-acne or dandruff formula, because the same US “cosmetic” may qualify as a “quasi-drug” in Korea and require a different registration pathway on the Korean side, even if you never intend to sell in Korea.

Which Ingredients Does Korea Prohibit Outright, and Where Is the Full List Published?

Korea maintains a prohibited list of over one thousand ingredients that cannot be used in any cosmetic product sold in South Korea. Included on this list are substances like galanthamine, gold salts, and a wide range of pharmacologically active molecules, hormones, and heavy metal compounds. The full list is published as Annex 1 (별표 1) of MFDS Notification No. 2026-16 and is available in Korean on the MFDS legal information portal (mfds.go.kr).

The prohibited list in Korea is broader than the FDA’s equivalent. The US FDA maintains a much shorter list of specifically prohibited or restricted cosmetic ingredients (roughly a dozen categories under 21 CFR 700). Korea’s prohibited list is closer in scope to the EU’s Annex II (about 1,600 entries in the EU CosIng database), though the individual entries diverge in the middle of the list. That means a formula that is fully MOCRA-permissible could still contain an ingredient Korea prohibits, and vice versa.

Practical consequence: if your ODM formulates for Korea by default and you plan to eventually launch in Korea (or use Korean e-commerce as an early channel), the Korean prohibited list is likely the more restrictive gate. If you are US-only, your ODM has already excluded these substances anyway, but you should ask for written confirmation that no Annex 1 ingredients appear in your formula so your MOCRA safety file has a clean starting record.

What Restricted Ingredients Come With Usage Limits US Founders Need to Read Carefully?

Beyond the prohibited list, Korea maintains a restricted list (Annex 2, 별표 2) that permits certain ingredients only under specific conditions: capped concentration, allowed product type, mandatory warning label, or leave-on versus rinse-off distinction. This is where most silent compliance issues surface for indie brands, because the ingredient itself is legal in both markets but the cap or the label warning differs.

Common examples that founders should double-check:

• Salicylic acid: permitted in rinse-off and leave-on cosmetics with different concentration caps, and requires a mandatory age-restriction warning at higher concentrations. The US does not require the same warning language in most cases.
• Formaldehyde-releasing preservatives: several are permitted in Korea with specific concentration caps and product-type restrictions. The EU has moved to ban several of these outright; Korea and the US still permit them at low concentration.
• Certain UV filters: Korea’s functional-cosmetic positive list for UV protection is closed. Any UV filter not on the list cannot appear at any concentration in a sunscreen sold in Korea. The US FDA sunscreen monograph list is different again, so a Korean-formulated sunscreen may need reformulation for US sale under the FDA OTC pathway.

The restricted list is the source of most “the formula passed in Korea but fails our US legal review” conversations we see. It also runs the other direction: a US-permitted ingredient at a US-permitted concentration may exceed the Korean cap. Either way, the fix is to get the ODM’s written confirmation of each restricted-list ingredient in your formula with its concentration and the Annex 2 reference.

How Does Korea's Functional Cosmetic Category Work, and Why Does It Matter to US Brands?

Korea recognizes five categories of “functional cosmetic” (기능성화장품): whitening, anti-wrinkle, rinse-off acne treatments, UV protection, and skin barrier restoration. A cosmetic that makes a claim in any of these categories must either use a pre-approved functional ingredient at a specified concentration or file a separate ingredient dossier with MFDS for review (source: ChemLinked functional cosmetic guide).

The whitening positive list contains nine approved ingredients (for example, arbutin at 2 to 5 percent per MFDS functional cosmetic reference at https://cosmetic.chemlinked.com/expert-article/decoding-south-korea-functional-cosmetic-regulation). The anti-wrinkle positive list contains four approved ingredients (for example, adenosine at 0.04 percent per the same MFDS reference at chemlinked.com). UV protection has its own closed positive list of permitted UV filters. Skin barrier restoration and rinse-off acne treatments have their own respective positive lists.

What this means for a US brand: if your Korean ODM formulates using functional-cosmetic positive-list ingredients at the exact approved concentration, the formula ships with the Korean functional-cosmetic clearance built in. If you are US-only, that Korean clearance is not required for MOCRA, but you inherit two useful things: a formula that will not surprise you with a Korean regulatory issue later if you decide to launch in Korea, and a well-documented efficacy justification for FDA-substantiated claim language on your US label.

Where founders get burned: asking a Korean ODM to formulate an aggressive whitening claim above the positive-list cap, or to combine multiple functional-cosmetic categories in a single SKU without the corresponding Korean clearance. This often triggers a re-formulation cycle that adds two to three months to a launch timeline.

How Do Korean and US Cosmetic Ingredient Rules Differ Under MOCRA 2026?

MOCRA is the Modernization of Cosmetics Regulation Act, the US statute that took effect December 29, 2022 and moved into active enforcement in 2026. Its ingredient-facing requirement is safety substantiation. Every product sold in the US must have “adequate substantiation of safety,” defined as tests, studies, research, analyses, or other evidence sufficient among qualified experts to support a reasonable certainty that the product is safe (source: Foley & Lardner MoCRA 2026 briefing).

Unlike Korea, MOCRA does not publish a functional-cosmetic positive list. It does not pre-approve claim-supporting concentrations. The FDA does maintain a short list of prohibited or restricted ingredients under 21 CFR 700 (bithionol, mercury compounds, vinyl chloride in aerosol propellants, and a small handful of others), and the OTC sunscreen monograph controls UV filter usage. Beyond that, MOCRA leaves the safety demonstration to the responsible person on the label.

In practice, the two systems are compatible but not equivalent:

Regulatory element	Korea (Cosmetic Act 2026)	US (MOCRA 2026)
Prohibited ingredient list	~1,000+ entries (Annex 1)	~12 categories (21 CFR 700)
Restricted ingredient list	Annex 2 with caps and product-type limits	No unified list; ingredient-by-ingredient safety demonstration
Functional cosmetic positive list	5 categories, closed lists	None; OTC sunscreen monograph controls UV filters only
Pre-market review	Required for functional cosmetics using non-listed ingredients	None for cosmetics; product listing (not approval) is required
Safety documentation	Held by ODM per KGMP	Held by responsible person per MOCRA substantiation rule

The gap that matters: MOCRA holds you (the responsible person on the US label) accountable for a safety substantiation file, but does not tell you what has to be in it. Korean ODMs generate KGMP-aligned documentation by default, and that documentation is a strong starting point for your MOCRA file. What it does not automatically include is US-specific stability data at US shipping and storage conditions, or US-language warning labels. You have to ask for both.

I'm Liz, Manhattan Founder Note

I'm Liz, I run altameet from Manhattan, NYC, and most of the compliance friction I see between US indie brands and Korean ODMs comes not from bad formulas but from missing paperwork nobody thought to request at the quote stage. If you want a quick gut-check on whether your current Korean ODM documentation will hold up under a MOCRA safety substantiation review, I'll give you 15 minutes free. Reach me at liz@altameet.com or book a slot at calendly.com/liz-altameet/gut-check.

What Should You Actually Ask Your Korean ODM Before You Sign a PO?

A pre-PO ingredient compliance checklist is the single highest-value document you can add to your Korean ODM engagement. Ask for the following in writing, before you commit to production:

1. Full INCI ingredient breakdown with weight percentages, cross-referenced to MFDS Annex 1 (prohibited), Annex 2 (restricted), and any functional-cosmetic positive list your formula uses.
2. Concentration confirmation for every ingredient on Annex 2 with the applicable cap and the reason your formula sits below it.
3. Warning label language for any restricted ingredient that triggers a mandatory Korean warning, plus written confirmation whether that same warning is required, recommended, or unnecessary in the US market.
4. Stability testing report per ICH Q1A(R2) or the equivalent MFDS/ISO reference, covering shelf-life claim across the temperature and humidity range your US logistics will actually see.
5. Microbial challenge test per ISO 11930, confirming preservative efficacy across the shelf-life window.
6. Impurity and heavy metal analysis to your US-side threshold (California Proposition 65 disclosures if you plan to sell in California).
7. KGMP documentation for the manufacturing site, plus the site’s FDA facility registration number if the site will manufacture your US SKU.
8. Non-notified ingredient disclosure confirming any raw material that has undergone MFDS individual review versus being drawn from the general positive list.

The compliance checklist above will not slow the quote turnaround if you ask for it up front. What slows a quote is asking for it after you have already agreed on price. Frame it as part of the initial brief so the ODM builds the documentation into the timeline.

What Are the Most Common Ingredient-Compliance Mistakes We See US Founders Make?

Reviewing typical patterns from public regulatory disclosures, the recurring failure modes cluster around a few predictable choices:

Assuming Korean approval equals US approval. A formula that clears MFDS review for a Korean functional-cosmetic whitening claim using arbutin within the positive-list cap is not automatically MOCRA-substantiated for the same claim on a US label. The Korean approval demonstrates efficacy under Korean protocol. Your MOCRA file needs a US-referenced substantiation trail, which the same underlying data usually supports, but requires you to package the data as a MOCRA substantiation record rather than an MFDS functional-cosmetic filing.

Skipping the restricted-list cross-check. Founders read the INCI list, recognize the ingredients as legal in the US, and assume the concentrations are safe. Some restricted-list ingredients cap out below what you might expect. The written concentration confirmation from your ODM prevents a later reformulation.

Confusing cosmetic with quasi-drug. A dandruff shampoo or anti-acne cleanser that reads as cosmetic in the US is often quasi-drug in Korea. If your ODM defaults to the quasi-drug pathway (because that is where the active-ingredient claim requires it in Korea), your product may carry Korean quasi-drug language that has no place on a US cosmetic label under MOCRA. Confirm the Korean product classification of the formula, not just the ingredient compliance.

Missing the label-warning gap. Some Korean warnings are longer or more specific than the FDA equivalent. The reverse is also true for FDA-mandated Drug Facts labeling on OTC sunscreens. If you use a Korean SPF formulation and try to sell it in the US without reformulating for the FDA sunscreen monograph, your label will fail FDA review. This is the single most common friction point between Korean SPF sourcing and US launch.

How Do You Document Ingredient Compliance for Both Markets?

The dual-market documentation file is your defensive record. Build it in parallel to the ODM engagement, not after the fact. A workable structure:

Section 1: Formula ledger. INCI list, weight percentages, function of each ingredient, source (raw material vendor), and cross-reference to MFDS Annex 1/2 and any US restricted list. This section changes only if the formula changes.

Section 2: Regulatory clearance. Korean functional-cosmetic filing number if applicable, MFDS non-notified ingredient review outcomes, EU CosIng entries for each ingredient (a useful third-party cross-check even if you are not selling in the EU), and US 21 CFR 700 confirmation.

Section 3: Safety substantiation. Stability data, microbial challenge test, HRIPT or equivalent human patch testing if used, ingredient-level safety data from raw material suppliers (SDS and toxicology summaries), and a written narrative that ties the evidence to the claim of “reasonable certainty of safety” MOCRA requires.

Section 4: Manufacturing controls. KGMP documentation, FDA facility registration for the manufacturing site, and the batch-by-batch CoA template you will receive at each production run.

Section 5: Label review. Your US label mock-up with each element (ingredient statement, net contents, principal display panel, warnings, responsible person contact) tied to the specific FDA regulation that governs it.

This file lives with the responsible person on the US label. If FDA inspects, this is what they will ask for. If you are ever pulled into a state attorney general inquiry over an ingredient claim, this is your defense.

Key Takeaways

• The Korean Cosmetic Act is a layered system: prohibited list (Annex 1), restricted list (Annex 2), functional-cosmetic positive lists, and hair-dye annex. The 2026 binding version is MFDS Notification No. 2026-16.
• Korean and US ingredient rules are compatible but not equivalent. Korean approval does not equal MOCRA substantiation, and Korean quasi-drug classification does not translate to US cosmetic labeling.
• Ask your Korean ODM for a written ingredient compliance packet at the quote stage: INCI breakdown, restricted-list cross-check, stability data, microbial challenge, and KGMP documentation.
• Build a dual-market documentation file yourself as the responsible person under MOCRA. The ODM cannot hold this file for you; the accountability is on the US label.
• SPF is the single most common reformulation trigger between Korean sourcing and US launch. Plan for a separate US SPF formula unless your Korean ODM confirms the UV filter set is on the FDA sunscreen monograph.

Frequently Asked Questions

Is a Korean-approved functional cosmetic automatically MOCRA-compliant in the US?

No. Korean functional-cosmetic approval demonstrates efficacy and safety under MFDS protocol, but does not constitute the MOCRA safety substantiation record required for US sale. The underlying data usually supports both, but you (as the responsible person on the US label) must package the evidence as a MOCRA substantiation file. This is a documentation exercise, not a re-testing exercise, if the ODM data is complete.

How often does MFDS update the Korean Cosmetic Act ingredient lists?

MFDS typically issues amendments to the ingredient safety standards once or twice a year. The 2026 binding version is Notification No. 2026-16, effective March 18, 2026, which reorganized the prohibited and restricted lists and added a new UV filter. Your Korean ODM tracks these updates and will typically flag any formula impact automatically, but you should confirm the notification version referenced in your ODM’s compliance letter.

Does the Korean Cosmetic Act apply to my product if I only sell in the US?

Not directly. If your product never enters the Korean market, it does not have to clear MFDS. However, because your product is manufactured in Korea, your Korean ODM will formulate to Korean standards by default and generate KGMP-aligned documentation. That documentation supports your MOCRA safety substantiation file in the US, so the Korean Cosmetic Act indirectly shapes the paperwork you receive at delivery.

What happens if my formula uses an ingredient not on any Korean positive list?

Your Korean ODM will either (a) not use it, (b) file a non-notified raw material review with MFDS, which adds several months and a review fee, or (c) redirect the formula to the quasi-drug pathway if the ingredient triggers a drug-adjacent claim. Option (a) is by far the most common. Confirm at the quote stage which route your ODM plans to take for any unusual active ingredient.

Do I need California Proposition 65 disclosures for Korean-manufactured products sold in California?

Yes, if any listed Proposition 65 chemical is present in the finished product above the safe-harbor threshold. Ask your Korean ODM for a heavy metal and impurity analysis that references Proposition 65 thresholds specifically. Korean KGMP heavy metal testing is generally more stringent than the safe-harbor threshold, but a written cross-reference in the ODM’s compliance letter is what protects your US label.

Where to Go Next

If you want to see how the Korean regulatory documentation feeds into the wider US market entry paperwork, our FDA import guide for Korean skincare walks through the customs, facility registration, and MOCRA product listing steps that follow ingredient clearance. For the manufacturer-registration side of the same story (the MFDS 제조업 등록 process the ODM handles on its side), see our MFDS cosmetic manufacturer registration guide. And if you are still choosing between direct-ODM engagement and a trading house, our direct vs trading house vs US broker comparison covers the tradeoffs. To zoom out on the full launch playbook, start with our complete guide to starting a K-beauty brand in 2026.

Reviewed for accuracy by ALTA MEET’s formulation consulting team.

Ready to pressure-test your Korean ODM compliance file? Book a free 15-minute gut-check with Liz: liz@altameet.com | calendly.com/liz-altameet/gut-check | Get a quote at altameet.com/contact.